Literature DB >> 18664490

Dynamics of component exchange at PML nuclear bodies.

Stefanie Weidtkamp-Peters1, Thorsten Lenser, Dmitri Negorev, Norman Gerstner, Thomas G Hofmann, Georg Schwanitz, Christian Hoischen, Gerd Maul, Peter Dittrich, Peter Hemmerich.   

Abstract

PML nuclear bodies (NBs) are involved in the regulation of key nuclear pathways but their biochemical function in nuclear metabolism is unknown. In this study PML NB assembly dynamics were assessed by live cell imaging and mathematic modeling of its major component parts. We show that all six nuclear PML isoforms exhibit individual exchange rates at NBs and identify PML V as a scaffold subunit. SP100 exchanges at least five times faster at NBs than PML proteins. Turnover dynamics of PML and SP100 at NBs is modulated by SUMOylation. Exchange is not temperature-dependent but depletion of cellular ATP levels induces protein immobilization at NBs. The PML-RARalpha oncogene exhibits a strong NB retention effect on wild-type PML proteins. HIPK2 requires an active kinase for PML NB targeting and elevated levels of PML IV increase its residence time. DAXX and BLM turn over rapidly and completely at PML NBs within seconds. These findings provide a kinetics model for factor exchange at PML NBs and highlight potential mechanisms to regulate intranuclear trafficking of specific factors at these domains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664490     DOI: 10.1242/jcs.031922

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  93 in total

Review 1.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

3.  N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.

Authors:  Prashant Sharma; Rodolfo Murillas; Huafeng Zhang; Michael R Kuehn
Journal:  J Cell Sci       Date:  2010-03-16       Impact factor: 5.285

Review 4.  Biogenesis of nuclear bodies.

Authors:  Miroslav Dundr; Tom Misteli
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-11-10       Impact factor: 10.005

5.  Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation.

Authors:  Yunyun Geng; Shamci Monajembashi; Anwen Shao; Di Cui; Weiyong He; Zhongzhou Chen; Peter Hemmerich; Jun Tang
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

6.  Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma.

Authors:  Wu-Hua Guo; Li-Hua Yuan; Zhi-Hua Xiao; Dan Liu; Ji-Xiang Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-26       Impact factor: 4.553

7.  JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress.

Authors:  Juhong Liu; Hye-Jung Chung; Matthew Vogt; Yetao Jin; Daniela Malide; Liusheng He; Miroslav Dundr; David Levens
Journal:  EMBO J       Date:  2011-02-01       Impact factor: 11.598

8.  Dynamics of telomeres and promyelocytic leukemia nuclear bodies in a telomerase-negative human cell line.

Authors:  Thibaud Jegou; Inn Chung; Gerrit Heuvelman; Malte Wachsmuth; Sabine M Görisch; Karin M Greulich-Bode; Petra Boukamp; Peter Lichter; Karsten Rippe
Journal:  Mol Biol Cell       Date:  2009-02-11       Impact factor: 4.138

9.  Assembly dynamics of PML nuclear bodies in living cells.

Authors:  Peter Brand; Thorsten Lenser; Peter Hemmerich
Journal:  PMC Biophys       Date:  2010-03-05

10.  SUMO modification regulates BLM and RAD51 interaction at damaged replication forks.

Authors:  Karen J Ouyang; Leslie L Woo; Jianmei Zhu; Dezheng Huo; Michael J Matunis; Nathan A Ellis
Journal:  PLoS Biol       Date:  2009-12-01       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.